Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease

/PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for…
Share This Post
Related Articles
Receive the latest updates

Subscribe To
Our Quarterly Newsletter

Get notified about new blog posts, case studies, white papers, and more!